Related Experiment Video
Updated: Apr 5, 2026
06:21
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
Published on: May 10, 2024
1.4K
PGWD: Integrating Personal Genome for Warfarin Dosing
Yidan Pan1, Ronghai Cheng1, Zhoufang Li1
1Department of Biology, South University of Science and Technology of China, Shenzhen, China.
Interdisciplinary Sciences, Computational Life Sciences
|August 13, 2015
Summary
Personal genome sequencing data can now inform warfarin dosing. PGWD is a new bioinformatics tool that uses high-throughput sequencing data for accurate warfarin dosage prediction, improving upon older methods.
Area of Science:
- Pharmacogenomics
- Bioinformatics
- Genetics
Background:
- Warfarin is a crucial anticoagulant for preventing thrombosis.
- Warfarin dosage is significantly influenced by genetic variations in CYP2C9 and VKORC1 genes.
- Current genetic variant detection methods (e.g., real-time PCR) are low-throughput.
Purpose of the Study:
- To develop a bioinformatics tool for accurate warfarin dosing using high-throughput genome sequencing data.
- To bridge the gap between advanced sequencing technologies and clinical warfarin dosage prediction.
Main Methods:
- Development of PGWD, a novel web-based bioinformatics tool.
- PGWD analyzes personal whole genome sequencing data.
- Integration of genetic information with clinical data for dosage calculation.
Main Results:
- PGWD accepts high-throughput genome sequencing data as input.
- The tool provides accurate warfarin dosage predictions.
- It offers an alternative to low-throughput methods for pharmacogenetic analysis.
Conclusions:
- PGWD enables precise warfarin dosing by leveraging personal genome sequencing.
- This tool enhances the clinical utility of high-throughput genetic data for pharmacogenomics.
- PGWD represents a significant advancement in personalized warfarin therapy.
More Related Videos
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
125
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
125
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
114
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
114
01:29Pharmacogenomics: Identification of New Drug Targets
86
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
86
01:29Pharmacogenetics and Pharmacogenomics: Overview
152
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
152
01:27Principles of Pharmacogenetics: Types of Genetic Variants
98
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
98
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
199
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
199